Cardinal Health has agreed to acquire a majority stake in GI Alliance, a gastroenterology management services organization, and Advanced Diabetes Supply Group for a combined total of $3.9 billion, ...

Dr. Ma currently serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., ...

Watch out, Gilead and Novartis ... As any cell therapy maker knows, initial supply can make or break a CAR-T roll out and has hindered others in the past. Autolus is confident in its supply chain ...

MARKHAM — ventureLAB, a global founder community for hardware technology and enterprise software companies in Canada, and Hudson Valley FastFab Inc. (HVFF), a company promoting advanced solutions in ...

Global Regenerative Medicine Market is valued at approximately USD 34.56 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 32.4% over the forecast period 2024-2032.

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Financial writer rates Janus International Group as a hold due to expected poor performance, driven by lower volume and price ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...

In the latest trading session, Gilead Sciences (GILD) closed at $88.08, marking a -0.77% move from the previous day. This move lagged the S&P 500's daily gain of 0.16%. Elsewhere, the Dow saw a ...

This website uses cookies to improve your experience. By continuing to use this website you are accepting our cookie policy. Some cookies are necessary to make the website work properly, for example ...